CA-ANDERSEN-GLOBAL
26.2.2021 11:53:13 CET | Business Wire | Pressemeddelelse
Andersen Global udvider til St. Vincent og Grenadinerne med samarbejdsfirmaet Baptiste & Co. Law Firm, og styrker dermed sin caribiske platform og tilføjer yderligere dækning i den sydlige del af regionen.
Baptiste & Co. Law Firm blev grundlagt i 1986 af administrerende partner, René M. Baptiste, som har mere end 40 års erfaring. Ud over grundlæggelsen af firmaet omfatter Renés bedrifter fuldgyldigt medlemskab af advokatsamfundet i St. Vincent og Grenadinerne, Antigua og Barbuda, Saint Kitts og Nevis; offentliggjorte artikler i tidsskriftet International Finance ; to tjenesteperioder som folkevalgt medlem af parlamentet og minister i St. Vincent og Grenadinerne; samt rollen som formand for organisationen af østlige caribiske staters forsamling. Derudover har hun mere end 50 års offentlig tjeneste, hvilket har resulteret i anerkendelse fra Hendes Majestæt Dronning Elizabeth II i form af udnævnelse til Commander of Saint Michael and Saint George (CMG) for tjenester inden for jura, international finans, kultur og politik.
Baptiste & Co. er et full service-advokatfirma, der er specialiseret i konkurs og insolvens, handelsret, kontrakter, familieret, ejendomsret, ejendomsplanlægning, intellektuel ejendomsret (varemærker) og fast ejendom. Firmaet, der er beliggende i Kingstown, yder juridisk rådgivning og tjenester til enkeltpersoner, offentlige og private virksomheder, kreditforeninger, banker, forsikringsselskaber og rederier, samt udenlandske regeringer og statslige virksomheder. Derudover leverer firmaets advokater tjenester i flere retskredse på naboøer og er strategisk placeret for at hjælpe med grænseoverskridende tjenester i ethvert område af firmaets praksisområder.
"Vi er glade for at samarbejde med ligesindede, der forstår og efterlever værdier bestående af gennemsigtighed og uafhængighed," sagde René. "Vores firma har forpligtet sig til at levere omfattende, uovertrufne løsninger, der overgår kundernes forventninger. At samarbejde med Andersen Globals medlemsfirmaer og samarbejdsfirmaer forbedrer vores evne til at levere synergistiske tjenester til vores kunder på både lokalt og internationalt niveau."
Bestyrelsesformand for Andersen Global og administrerende direktør for Andersen, Mark Vorsatz, tilføjede: "Vi har udviklet en stærk tilstedeværelse i Caribien og vil fortsætte med at tilføje bredde og dybde til vores platform i regionen. René og hendes teams engagement i forvaltning, mange års erfaring og viden om lokale og internationale retskredse adskiller dem fra andre firmaer på markedet. Tilføjelsen af Baptiste & Co. er endnu et vigtigt link til vores strategi i regionen."
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer bestående af skatte- og juraeksperter fra hele verden. Efter at være blevet etableret i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 7.000 eksperter globalt og er repræsenteret på mere end 255 lokaliteter via sine medlems- og samarbejdsfirmaer.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210226005233/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
